Everence Capital Management Inc. Cuts Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Everence Capital Management Inc. trimmed its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 18.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,380 shares of the company’s stock after selling 1,250 shares during the period. Everence Capital Management Inc.’s holdings in Prestige Consumer Healthcare were worth $420,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in shares of Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock valued at $108,000 after acquiring an additional 220 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares in the last quarter. Franklin Resources Inc. increased its position in Prestige Consumer Healthcare by 4.3% during the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after purchasing an additional 894 shares during the period. Sanctuary Advisors LLC raised its stake in shares of Prestige Consumer Healthcare by 11.0% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock worth $1,244,000 after buying an additional 1,715 shares in the last quarter. Finally, Coldstream Capital Management Inc. acquired a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at approximately $205,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. DA Davidson reiterated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Finally, StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Monday, December 30th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $76.88 on Monday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.95 and a fifty-two week high of $86.36. The business has a fifty day moving average of $80.50 and a 200-day moving average of $74.01. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s revenue for the quarter was down .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.07 EPS. As a group, analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is owned by insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.